Scientific Opinion on the substantiation of health claims related to Bifidobacterium animalis ssp. lactis Bb-12 and immune defence against pathogens (ID 863), decreasing potentially pathogenic gastro-intestinal microorganisms (ID 866), “natural immune function” (ID 924), reduction of symptoms of inflammatory bowel conditions (ID 1469) and maintenance of normal blood LDL-cholesterol concentrations (ID 3089) pursuant to Article 13(1) of Regulation (EC) No 1924/2006

Tabs

Article
Bifidobacterium animalis ssp. lactis Bb-12, pathogens, microorganisms, LDL-cholesterol, immune, inflammation, health claims
First published in the EFSA Journal
8 April 2011
Adopted
12 November 2010
Type
Opinion of the Scientific Committee/Scientific Panel
Abstract

No abstract available

Panel members at the time of adoption
Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, Hendrik van Loveren and Hans Verhagen.
Panel on Dietetic Products, Nutrition and Allergies
Contact
doi
10.2903/j.efsa.2011.2047
EFSA Journal 2011;9(4):2047 [20 pp.].
On request from
European Commission
Competing interests
One member of the Panel did not participate in the discussion on the subject referred to above because of potential conflicts of interest identified in accordance with the EFSA policy on declarations of interests.
Print on demand
Number of Pages
20